// trading_journal65.jsx
// PATH: C:\Users\James Cadbury\Dropbox\Claude-Fund\journal\trading_journal65.jsx
// SESSION: S52 CLOSE | DATE: Saturday 30 May 2026
// STATUS: WEEKEND SESSION CLOSE
// NEXT JOURNAL: trading_journal66.jsx
// processNotes.dropboxProtocol: "DIRECT WRITE CONFIRMED via filesystem MCP."

const session65 = {
  sessionNumber: 65,
  date: "2026-05-30",
  sessionLabel: "S52 CLOSE",
  dayOfWeek: "Saturday",
  sessionType: "WEEKEND_CLOSE — FULL SCAN + STAGE 1 COMPLETIONS + CGCT EXIT DECISION",
  timeZone: "GST (UTC+4) — Dubai",
  marketsOpen: false,
  executionNote: "CGCT market sell order submitted by user. Executes Monday 1 June at NYSE open (17:30 UAE).",

  // ─── PENDING EXECUTION — CONFIRMS MONDAY OPEN ────────────────────────────────
  pendingExecution: {
    ticker: "CGCT",
    action: "SELL",
    shares: 291,
    orderType: "MARKET",
    submittedBy: "User — Saturday 30 May 2026",
    executionWindow: "Monday 1 June 2026 at NYSE open — 17:30 UAE",
    expectedFillPrice: 12.63,
    expectedProceeds: 3675,
    expectedRealizedPnL: 679,
    avgCost: 10.295,
    rationale: [
      "SPAC deSPAC hangover pattern highly predictable — arb funds exit on listing day, shorts arrive, lock-up overhang in 6 months.",
      "87% redemption rate is consistent with current SPAC arbitrage norm (not a technology signal) but compressed capital structure ($136M vs planned $376M) creates near-term dilution risk.",
      "PIPE split between sponsor affiliate and single institution — weak signal vs multi-name institutional PIPE.",
      "Deal required last-minute financing amendments and sponsor promissory note — stress indicator.",
      "Base rate: average deSPAC returns -57% to -64% across 2020-2025 cohorts. >90% trade below $10 post-listing.",
      "QS peer comparison: SPAC merger 2020 at $10, briefly spiked to $130, now ~$6-7. Factorial at similar stage.",
      "Current $12.63 is 21% premium to $10.41 trust value — speculative enthusiasm before listing volatility.",
      "Re-entry strategy: watch FAC at $7.50 trigger after 10-15 sessions of free trading once hangover works through.",
      "Technology thesis intact — OEM validation (Mercedes-Benz, Stellantis, Hyundai, Kia) is genuine. Sell now to re-enter cheaper.",
    ],
    reEntryPlan: {
      ticker: "FAC",
      watchAlert: 7.50,
      reEntryZone: "$6.00-9.00",
      reEntryConditions: [
        "Minimum 10-15 sessions of FAC free trading completed.",
        "Post-listing arb selling has visibly stabilised (volume normalising).",
        "QS and SLDP not in active downtrend (sector sentiment check).",
        "Stage 1 completed at that price level before any entry.",
      ],
      rationale: "Re-entry at $6-9 vs $12.63 exit gives more technology thesis exposure for same SI-37 dollar risk.",
    },
  },

  // ─── POSITION UPDATES THIS SESSION ───────────────────────────────────────────
  stopUpdates: [
    { ticker: "ZETA", from: 17.47, to: 18.99, confirmedBy: "User" },
    { ticker: "IBM",  from: 244.47, to: 264.96, confirmedBy: "User" },
    { ticker: "CCL",  from: 23.00, to: 24.51, confirmedBy: "User", note: "$0.196 below avg cost $24.706 — acceptable near-breakeven protection on peace deal binary" },
    { ticker: "NCLH", from: 14.50, to: 15.98, confirmedBy: "User", note: "$0.066 above avg cost $15.914 — effectively risk-free" },
    { ticker: "AVAV", from: 155.00, to: 183.00, confirmedBy: "User", note: "Class action overhang. Stop $183 is $2.067 below avg cost $185.067 — max loss ~$31 if triggered" },
  ],

  // ─── FULL SCAN OUTPUTS — S52 ──────────────────────────────────────────────────
  weeklyDiscoveryScan: {
    screenE: {
      result: "No actionable 13D/13G signals identified via web search this session. Direct EDGAR API access required for reliable Screen E execution. SI-85 compliance: screen attempted, no intelligence surfaced.",
    },
    screenA: {
      candidates: [
        { ticker: "OKTA", status: "BLOCKED P13", note: "Gapped +30% to new 52wk high $121.45. P13 blocks. Add to UNIVERSE at $100-105 on consolidation." },
        { ticker: "MELI", status: "STAGE 1 COMPLETE — MONITORING", note: "See Stage 1 below." },
        { ticker: "ON",   status: "BLOCKED P13", note: "52wk high set 26 May at $129.13. Currently $124. P13 blocks. Insider buying signal genuine but must wait for -15% pullback." },
      ],
    },
    screenB: {
      candidates: [
        { ticker: "NVO", status: "STAGE 1 COMPLETE — MONITORING", note: "See Stage 1 below." },
      ],
    },
    screenC: {
      candidates: [
        { ticker: "CRM", status: "MONITORING — $178-182 pullback entry", note: "+8% post-beat from depressed base. Stage 1 complete from S44. Consensus $255.55 vs $190 current. Wait for gap fill." },
        { ticker: "DELL", status: "DO NOT ENTER", note: "P13 — at 52wk high post +33% gap. Watch $330-350 on pullback." },
      ],
    },
    screenD: {
      candidates: [
        { ticker: "SNOW", status: "REMOVED FROM SHORT WATCHLIST — UNIVERSE", note: "SaaSpocalypse thesis inverted. +34% revenue growth. Short thesis dead. Wait for ATH pullback to $150-160." },
      ],
    },
    macroThemes: [
      {
        theme: "SaaSpocalypse Inversion",
        summary: "CRM, SNOW, OKTA, DELL all reported strong beats in same week. AI is additive to SaaS, not cannibalising. Sector re-rating ongoing. ADBE June 11 gate more important as result.",
      },
      {
        theme: "Hardware AI Broadening",
        summary: "Dell FY27 guidance $165-169B vs $142.5B consensus. HPE up 17% on Dell result alone. AI infrastructure thesis broadening to enterprise hardware. HPE Stage 2 signal confirmed.",
      },
    ],
    universeAdditions: [
      { ticker: "OKTA", thesis: "AI agent identity security; GAAP profitable; 77% gross margin; post-gap consolidation needed" },
      { ticker: "MELI", thesis: "28 quarters 30%+ LatAm revenue growth; -38% from ATH on deliberate investment cycle, not structural" },
      { ticker: "ON",   thesis: "SiC power semiconductors; -35% ATH; $6.6M insider buying from 3 separate insiders Q2 2026" },
      { ticker: "NVO",  thesis: "GLP-1 leader at 11x earnings, 4.7% yield; near 52wk low; CagriSema setback temporary" },
      { ticker: "SNOW", thesis: "SaaSpocalypse inverted; 34% revenue growth; removed from SI-61 short list; wait for ATH pullback" },
    ],
  },

  // ─── STAGE 1 COMPLETIONS ──────────────────────────────────────────────────────
  stage1Completions: [
    {
      ticker: "MELI",
      result: "PASS — ELEVATE TO MONITORING",
      price: 1695.65,
      fiftyTwoWeekRange: { low: 1495.00, high: 2645.22 },
      drawdownFromATH_pct: 35.9,
      forwardPE: 42.02,
      revenueGrowth_Q1_YoY: 49,
      analystConsensusTarget: 2230.28,
      analystCount: 21,
      analystRating: "Buy (21 Buy, 0 Sell)",
      impliedUpside_pct: 31.5,
      nextEarnings: "2026-08-05",
      entryZone: { low: 1580, high: 1650 },
      stop: 1450,
      target: 2230,
      shares: 3,
      maxLoss_SI35: 510,
      RR: 3.6,
      tradeClassification: "Growth/thesis — T32 3:1 minimum applies. Passes.",
      P24check: "Earnings 5 August — 66 days from entry. Clean.",
      thesis: "Dominant LatAm e-commerce and fintech platform. 28 consecutive quarters of 30%+ revenue growth. Margin compression is deliberate investment-cycle spend (free shipping, logistics, credit buildout), not structural deterioration. Q1 2026: 49% revenue growth YoY, fastest in 4 years. EPS miss on loan-loss provisions — noise. Shipping cost reduction in Brazil accelerating (17% YoY). At 42x forward earnings on depressed investment-cycle EPS, severely discounted vs 28-quarter growth history. Mean reversion to $2,230 analyst target is the thesis, not multiple expansion.",
      risks: [
        "Margin compression timeline uncertain — management not providing clear endpoint.",
        "Brazil macro exposure — BRL weakness amplifies USD-reported losses.",
        "Nu Holdings and Amazon LatAm competing directly on credit and logistics.",
        "Goldman Sachs cut to $2,100 — not a bull.",
      ],
      action: "Do not chase. Wait for price to enter $1,580-1,650 zone. Could be Monday if market opens weak.",
    },
    {
      ticker: "NVO",
      result: "PASS — ELEVATE TO MONITORING (12-24 month patient thesis)",
      price: 44.19,
      fiftyTwoWeekRange: { low: 35.12, high: 81.44 },
      drawdownFromATH_pct: 46,
      peTrailingApprox: 10.9,
      dividendYield_pct: 4.7,
      analystConsensusTarget: 85.31,
      analystCount: 16,
      goldmanTarget: 41,
      impliedUpside_pct: 93,
      nextEarnings: "Early August 2026 (estimated)",
      entryZone: { low: 40, high: 44 },
      stop: 36,
      target: 65,
      shares: 83,
      maxLoss_SI35: 498,
      RR: 3.8,
      tradeClassification: "Growth/value thesis — T32 3:1 minimum applies. Passes.",
      P24check: "Earnings ~early August. Entry today 60+ days before earnings. Clean.",
      thesis: "Global GLP-1 leader with Ozempic and Wegovy franchises trading at 11x earnings with 4.7% dividend yield — priced for zero growth. CagriSema head-to-head loss versus Lilly's Zepbound is a setback but not structural destruction. Q1 2026 key insight: 80% of Wegovy pill users were new to GLP-1 (market expansion, not cannibalization). 2026 guided earnings decline is explicitly investment-cycle driven (DKK 55B capex buildout). Once investment intensity normalises, earnings recover. The GLP-1 market is on track to reach $100B+ globally by 2030 — large enough for two dominant players. Current price assumes Novo loses. Evidence suggests it does not, simply cedes the performance crown to Lilly while remaining a volume leader.",
      risks: [
        "Lilly competitive pressure intensifying — Mounjaro/Zepbound leading on efficacy.",
        "CagriSema FDA decision late 2026 — negative decision would remove next-gen hope.",
        "Guidance explicitly DOWN 5-13% in 2026 — this is not a temporarily depressed earnings story.",
        "Timeline 12-24 months minimum — not a quick trade.",
        "Goldman Sachs at $41 — near current price, limited consensus cushion at the low end.",
      ],
      caveats: "This is a patient value position. Only enter in the $40-44 zone. Do not chase above $44. The investment cycle completion and earnings recovery is the thesis — it takes time. If NVO opens Monday below $44, entry is immediate consideration. This is the fund's first healthcare position.",
      action: "NVO currently at $44.19 — at the top of the entry zone. If Monday opens flat or lower, first healthcare position may be actionable.",
    },
  ],

  // ─── WATCHLIST STATUS POST-S52 ────────────────────────────────────────────────
  watchlist: {
    active: [
      {
        ticker: "BKNG",
        entryZone: "$151-165",
        stop: 148,
        target: 224,
        shares: 32,
        condition: "Peace deal confirmed AND first pullback to $151-165. No gap chasing.",
      },
    ],
    monitoring: [
      { ticker: "META",  zone: "$570-610",     notes: "Stage 1 complete. Stop $525, target $750-800." },
      { ticker: "GTT.PA", zone: "EUR 170-175", notes: "OVERDUE STAGE 1. June 17 ex-dividend 18 days away. INITIATE MONDAY — T35 risk." },
      { ticker: "CRM",   zone: "$178-182",     notes: "Post-earnings pullback entry. Consensus $255. Stop $168. Gap fill entry only." },
      { ticker: "MELI",  zone: "$1,580-1,650", notes: "STAGE 1 COMPLETE. Stop $1,450. Target $2,230. 3 shares. R/R 3.6:1." },
      { ticker: "NVO",   zone: "$40-44",       notes: "STAGE 1 COMPLETE. Stop $36. Target $65. 83 shares. R/R 3.8:1. Patient 12-24m thesis. First healthcare position." },
    ],
    universe: [
      { ticker: "ADBE", notes: "STAGE 1 OVERDUE. June 11 earnings gate — 12 days. Initiate Monday without fail." },
      { ticker: "OKTA", notes: "At 52wk high post +30% gap. Wait for $100-105 consolidation. P13 blocks now." },
      { ticker: "ON",   notes: "At 52wk high. Insider signal genuine. Wait for -15% pullback to ~$110." },
      { ticker: "SNOW", notes: "Removed from SI-61 short list. Wait for post-ATH pullback to $150-160." },
      { ticker: "NOW",  notes: "Stage 1 pending." },
      { ticker: "TTD",  notes: "Stage 1 pending. Midterm elections H2 + Google antitrust." },
      { ticker: "AECOM", notes: "Peace reconstruction play." },
      { ticker: "Jacobs", notes: "Peace reconstruction play." },
    ],
    sectionN: {
      slotsUsed: 0,
      slotsAvailable: 4,
      priority: "GTT.PA — June 17 ex-dividend, Stage 1 MONDAY. IES GBP £477 available for deployment.",
      doNotEnter: ["CWR.L (rerated +989%)", "ITM.L (rerated +400%)"],
    },
    shortWatchlist_SI61: {
      removals: ["SNOW — SaaSpocalypse thesis inverted by Q1 results"],
      active: ["PLTR — dormant Q2 July", "AAL — watch", "SNOW — REMOVED"],
    },
  },

  // ─── MACRO UPDATE AT S52 CLOSE ────────────────────────────────────────────────
  macro: {
    WTI: 97.63,
    WTI_date: "2026-05-26",
    SI25_C1: "APPROACHING — NOT MET. 60-day ceasefire extension tentatively agreed at negotiator level. Awaiting Trump signature. NOT permanent reopening. SI-25 requires PERMANENT.",
    SI25_C2: "IMMINENT. $97.63 vs threshold $95.28. Gap $2.35. If deal signed, WTI gaps below threshold Monday.",
    SI25_protocol: "DO NOT execute SI-25 exit on 60-day deal. C1 requires permanent. Raise CCL/NCLH stops (done). Hold thesis positions.",
    fedRate: "3.50-3.75%",
    rateHikeProbability: "50-60%",
    CAPE: 39.1,
    BTC: "~$77K weekend. MSTR stopped 28 May at $148.76. No longer held.",
  },

  // ─── MANDATORY ACTIONS MONDAY 1 JUNE ──────────────────────────────────────────
  mondayActions: [
    { priority: 1,  action: "CGCT fill confirmation — verify proceeds ~$3,675 in USD cash. No GTC stop to cancel (CGCT had none)." },
    { priority: 2,  action: "Iran deal status — has Trump signed ceasefire extension over the weekend? First check before any trades." },
    { priority: 3,  action: "NVO — if opens at or below $44, first healthcare position is actionable. 83 shares, stop $36." },
    { priority: 4,  action: "MELI — if dips to $1,580-1,650, 3 shares, stop $1,450." },
    { priority: 5,  action: "GTT.PA Stage 1 — INITIATE IMMEDIATELY. June 17 ex-dividend 18 days away. T35 risk." },
    { priority: 6,  action: "ADBE Stage 1 — INITIATE IMMEDIATELY. June 11 earnings gate 12 days away." },
    { priority: 7,  action: "BKNG — if peace deal signed, assess entry at first pullback $151-165. Do not chase gap." },
    { priority: 8,  action: "CCL/NCLH — if SI-25 C1 met (deal signed AND Hormuz confirmed open): raise CCL to $24.51 (done), NCLH to $15.98 (done). Monitor whether further raises warranted." },
    { priority: 9,  action: "FAC watch alert — set price alert at $7.50 for re-entry research trigger once FAC trades freely." },
    { priority: 10, action: "IBM stop — consider raising from $264.96 to $270+ if IBM holds above $295 this week." },
    { priority: 11, action: "Verify all stop orders in IBKR match S52 confirmed levels (ZETA $18.99, IBM $264.96, CCL $24.51, NCLH $15.98, AVAV $183.00)." },
  ],

  // ─── NEW LESSONS THIS SESSION ─────────────────────────────────────────────────
  newLessons: [
    {
      code: "P33",
      lesson: "SPAC EXIT BEFORE DECONVERSION. When a SPAC is trading at a meaningful premium to trust value post-vote-approval but pre-listing, and the fund holds a position that has achieved its intended gain, sell before the FAC ticker conversion rather than holding through the post-listing hangover. The deSPAC hangover pattern (arb exits, shorts arrive, lock-up overhang) is systematic and predictable. Use it by selling into pre-listing optimism and re-entering post-hangover at structurally lower prices. Technology thesis intact throughout — only the entry price improves.",
    },
    {
      code: "P34",
      lesson: "HIGH SPAC REDEMPTION RATE INTERPRETATION. An 87% redemption rate on a SPAC does not signal institutional skepticism about the target company's technology or fundamentals. In the 2024-2026 SPAC market, redemption rates consistently exceed 90% because institutional arb investors enter SPACs as risk-free yield trades and redeem regardless of the merger target's quality. Redemption rate is a signal about the SPAC investor base composition, not about the target. What matters for technology thesis evaluation is: (1) quality and breadth of the PIPE investor base, (2) whether deal terms were amended under financial stress, and (3) whether OEM/customer validation is independent of SPAC dynamics.",
    },
    {
      code: "T60",
      lesson: "SELL-THEN-REENTER AS A DELIBERATE STRATEGY FOR DECONVERSION EVENTS. When a held position is converting from a SPAC structure to a freely traded equity and the fund has a gain at current price, the optimal strategy is to sell pre-conversion and systematically re-enter post-hangover at a lower price. This applies when: (a) the post-listing hangover pattern is highly predictable for the asset class, (b) the technology thesis has not changed, and (c) the capital can be redeployed more efficiently during the waiting period. The expected value of sell-and-reenter exceeds hold-through in SPAC conversions specifically because the hangover creates a reliable re-entry window 30-90 days post-listing.",
    },
  ],

  // ─── SESSION PERFORMANCE SUMMARY ─────────────────────────────────────────────
  sessionSummary: {
    netLiquidity: 107300,
    unrealisedPnL: 5902,
    positionsAfterCGCTSale: 11,
    pendingSales: 1,
    stopUpdatesConfirmed: 5,
    stage1Completions: 2,
    universeAdditions: 5,
    weeklyReviewStatus: "COMPLETE — covered in trading_journal64.jsx and this session",
    scanCompletionStatus: "All 5 screens attempted. Screen E limited by tooling. Screens A-D yielded 5 UNIVERSE additions.",
    keyDecisions: [
      "CGCT — SELL pre-conversion. Market order submitted. Re-entry plan set at FAC $7.50.",
      "MELI — Stage 1 PASS. MONITORING. Entry zone $1,580-1,650.",
      "NVO — Stage 1 PASS. MONITORING. Entry zone $40-44. First healthcare position.",
      "SNOW — Removed from SI-61 short watchlist.",
      "AVAV — Stop raised $155 → $183. Do not add.",
      "All 5 stop updates confirmed by user.",
    ],
  },

  // ─── METADATA ────────────────────────────────────────────────────────────────
  writtenBy: "Claude Sonnet 4.6",
  writtenAt: "2026-05-30",
  previousJournal: "trading_journal64.jsx",
  nextJournal: "trading_journal66.jsx",
  processNotes: {
    dropboxProtocol: "DIRECT WRITE CONFIRMED via filesystem MCP.",
    journalNumber: 65,
    sessionType: "S52 close — full weekend session including weekly scan, Stage 1 completions, CGCT exit decision.",
  },
};

export default session65;
